THRX - Theseus Pharmaceuticals, Inc. Stock Price, Fair Value and News

$4.06

Market Closed

THRX Stock Valuation Analysis

Valuation

Max Portfolio %

THRX Price Action

THRX RSI Chart

THRX Stock Valuation Analysis

Valuation

Max Portfolio %

THRX Valuation

THRX Price/Earnings (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

THRX Fundamentals

THRX Earnings

THRX Profitability

THRX Investor Care

Revenue & Growth

About Theseus Pharmaceuticals, Inc.

Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors. The company also develops THE-349, a fourth-generation selective epidermal growth factor receptor inhibitor to address C797X-mediated resistance to first- or later-line osimertinib treatment in patients with non-small cell lung cancer. Its development programs address drug resistance mutations in key driver oncogenes, which are mutated genes that cause cancer. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.

CEO	Dr. Timothy P. Clackson Ph.D.
WEBSITE	https://theseusrx.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	38